natgillin/translations-raw huggingface dataset:
Some of these reactions with <product name> have resulted in recurrent symptoms and required a longer period of observation and treatment. 
Nekatere od teh reakcij pri zdravilu <ime zdravila> so povzročile ponavljajoče se simptome in potrebno je bilo daljše obdobje opazovanja in zdravljenja.
Possible side effects [The following adverse drug reaction should be added with a frequency very rare (may affect up to 1 in 10,000 people)] 
Možni neželeni učinki [Dodati je treba naslednjo neželeno reakcijo na zdravila, ki se pojavlja zelo redko (pojavi se lahko pri največ 1 od 10 000 bolnikov)]
If you had these symptoms prior to treatment with cladribine, tell your doctor about any change in these symptoms. 
Če ste imeli te simptome pred začetkom zdravljenja s kladribinom, o kakršni koli njihovi spremembi obvestite zdravnika.
Physicians should consider PML in the differential diagnosis in patients with new or worsening neurological, cognitive or behavioural signs or symptoms. 
Zdravniki morajo PML upoštevati pri diferencialni diagnozi pri bolnikih z novimi ali napredujočimi nevrološkimi, kognitivnimi ali vedenjskimi znaki ali simptomi.
If an allergic reaction occurs, the drug should be discontinued and appropriate therapy should be instituted. 
Če se pojavi alergijska reakcija, je treba uporabo zdravila prekiniti in uvesti ustrezno zdravljenje.
A negative JCV PCR does not exclude PML. 
Za JCV negativen izvid PCR ne izključuje PML.
Undesirable effects Investigations 
Neželeni učinki
Serious skin reactions 
Resne kožne reakcije
These may all be symptoms of a serious and potentially fatal brain condition known as progressive multifocal leukoencephalopathy (PML). 
Kar koli od naštetega je lahko simptom resne in potencialno smrtne možganske bolezni, imenovane progresivna multifokalna levkoencefalopatija (PML).
Frequency ‘Not known': Jarisch-Herxheimer reaction (see section 4.4) 
Neznana pogostnost: Jarisch-Herxheimerjeva reakcija (glejte poglavje 4.4)
Medicinal products concerned: cladribine-containing products authorised for oncology indications. 
Zdravila, ki jih to zadeva: zdravila, ki vsebujejo kladribin in so bila odobrena za onkološke indikacije.
Patients with suspected PML should not receive further treatment with cladribine. 
Bolniki s sumom na PML ne smejo prejemati nadaljnjega zdravljenja s kladribinom.
Progressive multifocal leukoencephalopathy (PML) 
Progresivna multifokalna levkoencefalopatija (PML)
Patients should be reassured that this is a usually self-limiting consequence of antibiotic treatment of spirochete infections. 
Bolnikom je treba pojasniti, da gre za običajno posledico antibiotičnega zdravljenja okužb s spirohetami, ki izzveni sama.
PML was reported 6 months to several years after treatment with cladribine. 
O nastopu PML so poročali od šest mesecev do več let po zdravljenju s kladribinom.
Physicians should be aware that reappearance of the allergic symptoms may occur when symptomatic therapy is discontinued. 
Zdravniki se morajo zavedati, da se ob prekinitvi simptomatskega zdravljenja alergijski simptomi lahko ponovno pojavijo.
In case of AGEP diagnosis, acetazolamide should be discontinued and any subsequent administration of acetazolamide contraindicated. 
V primeru diagnoze AGEP je treba prenehati z jemanjem acetazolamida in tudi vsaka nadaljnja uporaba acetazolamida je kontraindicirana.
Talk to your doctor or pharmacist before taking this medicine: 
Pred začetkom jemanja tega zdravila se posvetujte z zdravnikom ali farmacevtom:
Patients at high risk for HAGMA are in particular those with severe renal impairment, sepsis or malnutrition especially if the maximum daily doses of paracetamol are used. 
Bolniki z velikim tveganjem za HAGMA so zlasti tisti s hudo okvaro ledvic, sepso ali nedohranjenostjo, še posebej pri uporabi največjega dnevnega odmerka paracetamola.
What you need to know before taking <product name> Warnings and precautions 
Kaj morate vedeti, preden boste vzeli zdravilo <ime zdravila> Opozorila in previdnostni ukrepi
Some patients with spirochete infections may experience a Jarisch-Herxheimer reaction shortly after doxycycline treatment is started. 
Nekateri okuženi bolniki lahko kmalu po začetku zdravljenja z doksiciklinom doživijo JarischHerxheimerjevo reakcijo.
Severe bullous reactions 
Hude bulozne reakcije
High anion gap metabolic acidosis is a serious disease that must have urgent treatment. 
Presnovna acidoza s povečano anionsko vrzeljo je resna bolezen, ki jo je treba nujno zdraviti.
Additional follow-up and evaluation may be warranted if no alternative diagnosis can be established. 
Če ni mogoče postaviti alternativne diagnoze, sta upravičena dodatno spremljanje in diagnostika.
Rare: skin eruption that is characterised by the rapid appearance of areas of red skin studded with small pustules (small blisters filled with white/yellow fluid). 
Redki: kožna reakcija, za katero je značilen hiter pojav predelov rdeče kože, polnih majhnih pustul (mehurčkov, napolnjenih z belo/rumeno tekočino).
Suggested evaluation for PML includes neurology consultation, magnetic resonance imaging of the brain, and cerebrospinal fluid analysis for JC virus (JCV) DNA by polymerase chain reaction (PCR) or a brain biopsy with testing for JCV. 
Predlagana diagnostika za PML vključuje nevrološko posvetovanje, magnetnoresonančno slikanje možganov in analizo cerebrospinalnega likvorja za DNK virusa JC (JCV) z verižno reakcijo s polimerazo (PCR, polymerase chain reaction) ali biopsijo možganov s preiskavo za JCV.
If flucloxacillin is continued after cessation of paracetamol, it is advisable to ensure that there are no signals of HAGMA, as there is a possibility of flucloxacillin maintaining the clinical picture of HAGMA (see section 4.5). 
Če se zdravljenje s flukloksacilinom nadaljuje po prenehanju zdravljenja s paracetamolom, se je priporočljivo prepričati, da ni znakov HAGMA, saj obstaja možnost, da flukloksacilin ohranja klinično sliko HAGMA (glejte poglavje 4.5).
If any of the side effects listed below occur, contact your doctor as soon as possible: - the Jarisch-Herxheimer reaction which causes fever, chills, headache, muscle pain, and skin rash that is usually self-limiting. 
Če se pojavi kateri koli od naslednjih neželenih učinkov, se čim prej posvetujte z zdravnikom: - Jarisch-Herxheimerjeva reakcija, ki povzroča vročino, mrzlico, glavobol, bolečine v mišicah in kožni izpuščaj.
After co-administration of flucloxacillin and paracetamol, a close monitoring is recommended in order to detect the appearance of acid-base disorders, namely HAGMA, including the search of urinary 5oxoproline. 
Po sočasnem dajanju flukloksacilina in paracetamola se priporoča natančno spremljanje, da se ugotovi pojav kislinsko-bazičnih motenj, tj. HAGMA, vključno z iskanjem 5-oksoprolina v urinu.
Talk to your doctor <or> <pharmacist> <or nurse> before <taking> <using> <product name> At any time during or after your treatment, tell your doctor or nurse immediately if you: experience blurred, loss of or double vision, difficulty speaking, weakness in an arm or a leg, a change in the way you walk or problems with your balance, persistent numbness, decreased sensation or loss of sensation, memory loss or confusion. 
Če se kadar koli med zdravljenjem ali po njem pojavi kaj od naslednjega, o tem takoj obvestite zdravnika ali medicinsko sestro: zamegljen vid, izguba vida ali dvojni vid, težave pri govorjenju, oslabelost roke ali noge, sprememba načina hoje ali težave z ravnotežjem, dolgotrajna otrplost, zmanjšano zaznavanje ali izguba zaznavanja, izguba spomina ali zmedenost.
Cladribine - Progressive multifocal leukoencephalopathy (PML) (EPITT no 18875) 
Kladribin - progresivna multifokalna levkoencefalopatija (PML) (št. EPITT 18875)
The occurrence at the treatment initiation of a feverish generalised erythema associated with pustula may be a symptom of acute generalised exanthematous pustulosis (AGEP) (see section 4.8). 
Pojav vročinskega generaliziranega eritema, povezanega s pustulo, na začetku zdravljenja je lahko simptom akutne generalizirane eksantematozne pustuloze (AGEP) (glejte poglavje 4.8).
As with other macrolides, rare serious allergic reactions, including acute generalised exanthematous pustulosis (AGEP) have been reported. 
Kot pri ostalih makrolidih so poročali o redkih resnih alergijskih reakcijah, vključno z akutno generalizirano eksantematozno pustulozo (AGEP).
There is a risk of blood and fluid abnormality (high anion gap metabolic acidosis) which occurs when there is an increase in plasma acidity, when flucloxacillin is used concomitantly with paracetamol, particularly in certain groups of patients at risk, e.g. patients with severe renal impairment, sepsis or malnutrition, especially if the maximum daily doses of paracetamol are used. 
Obstaja tveganje nenormalnosti krvi in telesnih tekočin (presnovna acidoza s povečano anionsko vrzeljo), do česar pride pri povečani kislosti plazme, kadar se flukloksacilin in paracetamol uporabljata sočasno, zlasti pri nekaterih ogroženih skupinah bolnikov, npr. bolnikih s hudo okvaro ledvic, sepso ali nedohranjenostjo, še posebej pri uporabi največjih dnevnih odmerkov paracetamola.
As with erythromycin and other macrolides, rare serious allergic reactions, including angioneurotic oedema and anaphylaxis (rarely fatal), dermatologic reactions including acute generalised exanthematous pustulosis (AGEP), Stevens Johnson syndrome (SJS), toxic epidermal necrolysis (TEN) (rarely fatal) and drug reaction with eosinophilia and systemic symptoms (DRESS) have been reported. 
Kot pri eritromicinu in drugih makrolidih so poročali o redkih resnih alergijskih reakcijah, vključno z angionevrotičnim edemom in anafilaksijo (redko s smrtnim izidom), dermatološkimi reakcijami, vključno z akutno generalizirano eksantematozno pustulozo (AGEP), Stevens-Johnsonovim sindromom (SJS), toksično epidermalno nekrolizo (TEN) (redko s smrtnim izidom) in reakcijo na zdravilo z eozinofilijo in sistemskimi simptomi (DRESS).
If symptoms or signs of AGEP, SJS or TEN (e.g. progressive skin rash often with blisters or mucosal lesions) are present, roxithromycin treatment should be discontinued. 
V prisotnosti simptomov ali znakov AGEP, SJS ali TEN (npr. napredujočega kožnega izpuščaja z mehurji ali lezijami na sluznicah) je treba zdravljenje z roksitromicinom prekiniti.
Desloratadine; loratadine - Weight increased in children (EPITT no 18906) 
Desloratadin; loratadin - povečana telesna masa pri otrocih (št. EPITT 18906)
An association with prolonged lymphopenia has been reported in several of these cases. 
Pri več od teh primerov so poročali o povezavi z dolgotrajno limfopenijo.
Acetazolamide - Acute generalised exanthematous pustulosis (AGEP) (EPITT no 18892) 
Acetazolamid - akutna generalizirana eksantematozna pustuloza (AGEP)(št. EPITT 18892)
This occurs shortly after starting doxycycline treatment for infections with spirochete such as Lyme disease. 
Ta reakcija običajno izgine sama od sebe. Do tega pride kmalu po začetku zdravljenja okužb s spirohetami, npr. lymske borelioze, z doksiciklinom.
Cases of PML, including fatal cases, have been reported with cladribine. 
Pri zdravljenju s kladribinom so poročali o primerih PML, vključno s smrtnim izidom.
Doxycycline - Doxycycline induced Jarisch-Herxheimer reaction (EPITT no 18937) 
Doksiciklin - z doksiciklinom inducirana JarischHerxheimerjeva reakcija (št. EPITT 18937)
Post marketing experience: very rare cases of high anion gap metabolic acidosis, when flucloxacillin is used concomitantly with paracetamol, generaly in the presence of risk factors (see section 4.4.) 
Izkušnje z zdravilom po začetku trženja: zelo redki primeri presnovne acidoze s povečano anionsko vrzeljo, če se flukloksacilin uporablja sočasno s paracetamolom, običajno v prisotnosti dejavnikov tveganja (glejte poglavje 4.4).
Very rare cases of blood and fluid abnormality (high anion gap metabolic acidosis) which occurs when there is an increase in plasma acidity, when flucloxacillin is used concomitantly with paracetamol, generaly in the presence of risk factors (see section 2). 
Zelo redki primeri nenormalnosti krvi in telesnih tekočin (presnovna acidoza s povečano anionsko vrzeljo), do česar pride pri povečani kislosti plazme, kadar se flukloksacilin in paracetamol uporabljata sočasno, običajno v prisotnosti dejavnikov tveganja (glejte poglavje 2).
Azithromycin; clarithromycin; erythromycin; roxithromycin - Acute generalised exanthematous pustulosis (AGEP) (EPITT no 18891) 
Azitromicin, klaritromicin, eritromicin, roksitromicinakutna generalizirana eksantematozna pustuloza (AGEP)(št. EPITT 18891)
Interaction with other medicinal products and other forms of interaction Caution should be taken when flucloxacillin is used concomitantly with paracetamol as concurrent intake has been associated with high anion gap metabolic acidosis, especially in patients with risk factors. 
Medsebojno delovanje z drugimi zdravili in druge oblike interakcij Pri sočasni uporabi flukloksacilina in paracetamola je potrebna previdnost, saj je sočasno jemanje, zlasti pri bolnikih z dejavniki tveganja, povezano s presnovno acidozo s povečano anionsko vrzeljo.
If a widespread, severe skin rash occurs, including skin blistering or peeling, as well as signs of flu and fever (Stevens-Johnson syndrome), a general unwell feeling, fever, chills and muscle aches (toxic epidermal necrolysis), or a red, scaly rash with bumps under the skin and blisters (acute generalised exanthematous pustulosis), refer to a doctor immediately since these skin effects may be lifethreatening. 
Kaj morate vedeti, preden boste vzeli zdravilo <ime zdravila> Če se pojavi razširjen, hud kožni izpuščaj, vključno z mehurji na koži ali luščenjem kože, ter znaki gripe in povišana telesna temperatura (Stevens-Johnsonov sindrom), splošno slabo počutje, povišana telesna temperatura, mrazenje in bolečine v mišicah (toksična epidermalna nekroliza) ali rdeč, luskast izpuščaj s podkožnimi bulicami in mehurji (akutna generalizirana eksantematozna pustuloza), se takoj obrnite na zdravnika, saj so ti kožni učinki lahko življenjsko nevarni.
Possible side effects Frequency ‘not known': weight increased 
Možni neželeni učinki Neznana pogostnost: povečana telesna masa
What you need to know before you <take> <use> <product name> 
Kaj morate vedeti, preden boste <vzeli> <uporabili> zdravilo <ime zdravila> Opozorila in previdnostni ukrepi
Flucloxacillin - High anion gap metabolic acidosis (HAGMA) (EPITT no 18844) 
Flukloksacilin - presnovna acidoza s povečano anionsko vrzeljo (HAGMA) (EPITT, št. 18844)
Caution is advised when flucloxacillin is administered concomitantly with paracetamol due to the increased risk of high anion gap metabolic acidosis (HAGMA). 
Pri sočasnem dajanju flukloksacilina in paracetamola se zaradi povečanega tveganja za presnovno acidozo s povečano anionsko vrzeljo (HAGMA, high anion gap metabolic acidosis) priporoča previdnost.
Frequency ‘not known': weight increased, increased appetite 
Neznana pogostnost: povečana telesna masa, povečan tek
Cases of severe bullous skin reactions such as Stevens Johnson syndrome, toxic epidermal necrolysis and acute generalised exanthematous pustulosis (AGEP), have been reported with roxithromycin. 
Pri roksitromicinu so poročali o primerih hudih buloznih kožnih reakcij, kot so Stevens-Johnsonov sindrom, toksična epidermalna nekroliza in akutna generalizirana eksantematozna pustuloza (AGEP).
Acute generalised exanthematous pustulosis (AGEP), Stevens-Johnson Syndrome, toxic epidermal necrolysis and drug rash with eosinophilia and systemic symptoms (DRESS)), clarithromycin therapy should be discontinued immediately and appropriate treatment should be urgently initiated. 
V primeru resnih akutnih preobčutljivostnih reakcij, kot so anafilaksija, hudi akutni kožni neželeni učinki (npr. akutna generalizirana eksantematozna pustuloza (AGEP), Stevens-Johnsonov sindrom, toksična epidermalna nekroliza in z zdravilom povezan izpuščaj z eozinofilijo in sistemskimi simptomi (DRESS)), je treba zdravljenje s klaritromicinom takoj prekiniti in nujno uvesti ustrezno zdravljenje 4.8.
Metabolism and nutrition disorders Frequency ‘not known': increased appetite 
Neznana pogostnost: povečana telesna masa Presnovne in prehranske motnje Neznana pogostnost: povečan tek Navodilo za uporabo
Skin and subcutaneous tissue disorders Rare: acute generalised exanthematous pustulosis (AGEP) 
Neznana pogostnost: akutna generalizirana eksantematozna pustuloza (AGEP)
Not known: acute generalised exanthematous pustulosis (AGEP) 
Redki: akutna generalizirana eksantematozna pustuloza (AGEP)
Contact a doctor immediately if you experience a serious skin reaction: a red, scaly rash with bumps under the skin and blisters (exanthematous pustulosis). 
Če se pri vas pojavi resna kožna reakcija: rdeč, luskast izpuščaj s podkožnimi bulicami in mehurji (eksantematozna pustuloza), se nemudoma obrnite na zdravnika.
This summary was last updated in 10-2014. 
Povzetek je bil nazadnje posodobljen 10-2014.
The European Commission granted a marketing authorisation valid throughout the European Union for Prezista on 12 February 2007. 
Evropska komisija je dovoljenje za promet z zdravilom Prezista, veljavno po vsej Evropski uniji, izdala 12. februarja 2007.
Other information about Prezista 
Druge informacije o zdravilu Prezista
What measures are being taken to ensure the safe and effective use of Prezista? 
Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Prezista?
It is available as tablets (75, 150, 300, 400, 600, and 800 mg) and as an oral suspension (100 mg/ml). 
Na voljo je v obliki tablet (75, 150, 300, 400, 600 in 800 mg) in kot peroralna suspenzija (100 mg/ml).
The full EPAR for Prezista can be found on the Agency's website ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports. 
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Prezista je na voljo na spletni strani agencije ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
In adults, Prezista has been studied in six main studies. 
Pri odraslih so zdravilo Prezista proučevali v šestih glavnih študijah.
It blocks an enzyme called protease, which is involved in the reproduction of HIV. 
Zavira encim, imenovan proteaza, ki sodeluje pri razmnoževanju virusa HIV.
The oral suspension is available for patients unable to swallow the tablets. 
Peroralna suspenzija je na voljo za bolnike, ki ne morejo pogoltniti tablet.
A risk management plan has been developed to ensure that Prezista is used as safely as possible. 
Za zagotovitev čim varnejše uporabe zdravila Prezista je bil pripravljen načrt obvladovanja tveganj.
For more information about treatment with Prezista, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. 
Za več informacij o zdravljenju z zdravilom Prezista preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
This is a summary of the European public assessment report (EPAR) for Prezista. 
To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Prezista.
What benefit has Prezista shown during the studies? 
Kakšne koristi je zdravilo Prezista izkazalo med študijami?
The main measures of effectiveness were based on the change in HIV levels in the blood (viral load). 
Glavna merila učinkovitosti so temeljila na spremembi ravni virusa HIV v krvi (virusnega bremena).
The CHMP decided that Prezista's benefits are greater than its risks and recommended that it be given marketing authorisation. 
CHMP je zaključil, da so koristi zdravila Prezista večje od z njim povezanih tveganj, in priporočil, da se zanj izda dovoljenje za promet.
Side effects are similar in children and adolescents. 
Pri otrocih in mladostnikih prihaja do podobnih neželenih učinkov.
The 300- and 600-mg tablets contain a colouring agent called sunset yellow (E110), which can cause allergies. 
300- in 600-miligramske tablete vsebujejo oranžno rumeno barvilo (E110), ki lahko povzroči alergije.
It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Prezista. 
Pojasnjuje, kako je Odbor za zdravila za uporabo v humani medicini (CHMP) ocenil to zdravilo, na podlagi česar je oblikoval mnenje za izdajo dovoljenja za promet z njim in priporočila glede pogojev njegove uporabe.
Immune reconstitution syndrome happens when the patient's immune system starts working again and fights existing infections, causing inflammation at the site of the infection. 
Sindrom imunske reaktivacije nastopi, ko začne bolnikov imunski sistem ponovno delovati in se boriti proti obstoječim okužbam, kar povzroči vnetje na okuženem mestu.
The study included both previously treated patients and those who had not received HIV medicines before. 
Študija je vključevala predhodno zdravljene bolnike in tudi tiste, ki zdravil za zdravljenje okužbe z virusom HIV predhodno še niso prejemali.
In adults who had not been treated before, Prezista was as effective as lopinavir. 
Pri odraslih, ki predhodno niso bili zdravljeni, je bilo zdravilo Prezista enako učinkovito kot lopinavir.
What is the risk associated with Prezista? 
Kakšna tveganja so povezana z zdravilom Prezista?
Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Prezista, including the appropriate precautions to be followed by healthcare professionals and patients. 
V skladu s tem načrtom so bile v povzetek glavnih značilnosti tega zdravila in navodilo za njegovo uporabo vključene informacije o varnosti, vključno s previdnostnimi ukrepi, ki jih morajo upoštevati zdravstveni delavci in bolniki.
Prezista is a medicine that contains the active substance darunavir. 
Prezista je zdravilo, ki vsebuje zdravilno učinkovino darunavir.
Either ritonavir or cobicistat is used with Prezista as a ‘booster'. 
Ritonavir ali kobicistat se z zdravilom Prezista uporabljata kot „spodbujevalca“.
Prezista must not be taken by patients who have severely reduced liver function, or who are taking certain other medicines which may decrease blood levels of darunavir, ritonavir or cobicistat, and therefore cause a lack of effect. 
Zdravilo Prezista se ne sme uporabljati pri bolnikih, ki imajo hudo zmanjšano jetrno funkcijo ali jemljejo druga zdravila, ki lahko znižujejo ravni darunavirja, ritonavirja in kobicistata v krvi, ter tako zmanjšujejo njegov učinek.
Why has Prezista been approved? 
Zakaj je bilo zdravilo Prezista odobreno?
When the enzyme is blocked, the virus does not reproduce normally and its rate of replication slows down. 
Ko je encim zavrt, se virus ne razmnožuje več normalno, ampak upočasnjeno.
Patients who are allergic to this agent may need to take the lower strength tablets, which do not contain sunset yellow. 
Bolniki, ki so alergični nanj, bodo morda morali jemati tablete manjše jakosti, ki tega barvila ne vsebujejo.
Prezista does not cure HIV infection or AIDS, but it may delay or reverse the damage to the immune system and the development of infections and diseases associated with AIDS. 
Zdravilo ne ozdravi okužbe z virusom HIV ali aidsa, vendar pa lahko upočasni slabšanje imunskega sistema ali izboljša njegovo stanje ter zavira razvoj okužb in bolezni, povezanih z aidsom.
The active substance in Prezista, darunavir, is a protease inhibitor. 
Zdravilna učinkovina zdravila Prezista, darunavir, je zaviralec proteaze.
For the full list of these medicines, see the package leaflet. 
Za celoten seznam teh zdravil glejte navodilo za uporabo.
Prezista, taken in combination with other HIV medicines, reduces the amount of HIV in the blood and keeps it at a low level. 
Če se zdravilo Prezista jemlje v kombinaciji z drugimi zdravili za zdravljenje okužbe z virusom HIV, zmanjša količino tega virusa v krvi in ga ohranja na nizki ravni.
This allows a lower dose of darunavir to be used for the same antiviral effect. 
Uporaba spodbujevalca omogoča uporabo manjšega odmerka darunavirja za dosego enakega protivirusnega učinka.